GOODWILL AND OTHER INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

GOODWILL AND OTHER INTANGIBLE ASSETS

	Estimated Useful Lives	December 31,
Dollars in Millions		2019			2018
Goodwill(a)		$	22,488		$	6,538
Other intangible assets(a):
Licenses	5 – 15 years	482			510
Acquired developed product rights	3 – 15 years	46,827			2,357
Capitalized software	3 – 10 years	1,297			1,156
IPRD		19,500			32
Gross other intangible assets		68,106			4,055
Less accumulated amortization		(4,137		)	(2,964		)
Other intangible assets		$	63,969		$	1,091

(a) Includes goodwill and other intangible assets recognized as part of the Celgene acquisition in 2019. Refer to “—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements” for more information related to the Celgene acquisition.

Amortization expense of other intangible assets was $1,255 million in 2019, $198 million in 2018 and $190 million in 2017. Future annual amortization expense of other intangible assets is expected to be approximately $9.3 billion in 2020, $9.3 billion in 2021, $9.1 billion in 2022, $8.4 billion in 2023, and $7.4 billion in 2024.

Other intangible asset impairment charges were $66 million in 2019, $84 million in 2018 and $80 million in 2017. A $32 million IPRD impairment charge was recorded in Research and development in 2019 following a decision to discontinue development of an investigational compound obtained in the acquisition of Medarex. A $64 million impairment charge was recorded in Other (income)/expense, net in 2018 for an out-licensed asset obtained in the 2010 acquisition of ZymoGenetics, Inc., which did not meet its primary endpoint in a Phase II clinical study. A $75 million IPRD impairment charge was recognized and attributed to noncontrolling interest in 2017 after the option to purchase F-Star was not exercised.